180 related articles for article (PubMed ID: 28668829)
1. Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
Nath K; Nelson DS; Roman J; Putt ME; Lee SC; Leeper DB; Glickson JD
Anticancer Res; 2017 Jul; 37(7):3413-3421. PubMed ID: 28668829
[TBL] [Abstract][Full Text] [Related]
2. Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine.
Prabhakara S; Kalia VK
Indian J Med Res; 2008 Aug; 128(2):140-8. PubMed ID: 19001677
[TBL] [Abstract][Full Text] [Related]
3. (31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan.
Nath K; Nelson DS; Ho AM; Lee SC; Darpolor MM; Pickup S; Zhou R; Heitjan DF; Leeper DB; Glickson JD
NMR Biomed; 2013 Jan; 26(1):98-105. PubMed ID: 22745015
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice.
Nath K; Nelson DS; Putt ME; Leeper DB; Garman B; Nathanson KL; Glickson JD
PLoS One; 2016; 11(6):e0157125. PubMed ID: 27285585
[TBL] [Abstract][Full Text] [Related]
5. Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts and sensitization to melphalan.
Nath K; Nelson DS; Heitjan DF; Zhou R; Leeper DB; Glickson JD
NMR Biomed; 2015 Mar; 28(3):395-403. PubMed ID: 25702942
[TBL] [Abstract][Full Text] [Related]
6. The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
Tentori L; Dorio AS; Mazzon E; Muzi A; Sau A; Cuzzocrea S; Vernole P; Federici G; Caccuri AM; Graziani G
Eur J Cancer; 2011 May; 47(8):1219-30. PubMed ID: 21269821
[TBL] [Abstract][Full Text] [Related]
7. Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin.
Nath K; Roman J; Nelson DS; Guo L; Lee SC; Orlovskiy S; Muriuki K; Heitjan DF; Pickup S; Leeper DB; Blair IA; Putt ME; Glickson JD
Sci Rep; 2018 Oct; 8(1):14654. PubMed ID: 30279592
[TBL] [Abstract][Full Text] [Related]
8. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Tentori L; Leonetti C; Scarsella M; D'Amati G; Vergati M; Portarena I; Xu W; Kalish V; Zupi G; Zhang J; Graziani G
Clin Cancer Res; 2003 Nov; 9(14):5370-9. PubMed ID: 14614022
[TBL] [Abstract][Full Text] [Related]
9. Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells.
Chen M; Rose AE; Doudican N; Osman I; Orlow SJ
Mol Cancer Res; 2009 Dec; 7(12):1946-53. PubMed ID: 19934274
[TBL] [Abstract][Full Text] [Related]
10. Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.
Clemente N; Ferrara B; Gigliotti CL; Boggio E; Capucchio MT; Biasibetti E; Schiffer D; Mellai M; Annovazzi L; Cangemi L; Muntoni E; Miglio G; Dianzani U; Battaglia L; Dianzani C
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364157
[TBL] [Abstract][Full Text] [Related]
11. Optical Redox Imaging of Lonidamine Treatment Response of Melanoma Cells and Xenografts.
Xu HN; Feng M; Nath K; Nelson D; Roman J; Zhao H; Lin Z; Glickson J; Li LZ
Mol Imaging Biol; 2019 Jun; 21(3):426-435. PubMed ID: 30151646
[TBL] [Abstract][Full Text] [Related]
12. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Caporali S; Alvino E; Starace G; Ciomei M; Brasca MG; Levati L; Garbin A; Castiglia D; Covaciu C; Bonmassar E; D'Atri S
Pharmacol Res; 2010 May; 61(5):437-48. PubMed ID: 20026273
[TBL] [Abstract][Full Text] [Related]
13. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Fateh S; Schell TD; Gingrich R; Neves RI; Drabick JJ
Cancer Biol Ther; 2010 Dec; 10(11):1091-7. PubMed ID: 20930514
[TBL] [Abstract][Full Text] [Related]
14. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
15. Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin.
Nath K; Nelson DS; Heitjan DF; Leeper DB; Zhou R; Glickson JD
NMR Biomed; 2015 Mar; 28(3):281-90. PubMed ID: 25504852
[TBL] [Abstract][Full Text] [Related]
16. Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Cheng Y; Sk UH; Zhang Y; Ren X; Zhang L; Huber-Keener KJ; Sun YW; Liao J; Amin S; Sharma AK; Yang JM
PLoS One; 2012; 7(4):e35104. PubMed ID: 22496897
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.
Jiang G; Sun C; Li RH; Wei ZP; Zheng JN; Liu YQ
J Cancer Res Clin Oncol; 2015 Jan; 141(1):75-85. PubMed ID: 25103017
[TBL] [Abstract][Full Text] [Related]
18. Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro.
Ryabaya OO; Inshakov AN; Egorova AV; Emelyanova MA; Nasedkina TV; Zasedatelev AS; Khochenkov DA; Stepanova EV
Anticancer Drugs; 2017 Mar; 28(3):307-315. PubMed ID: 27941537
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
Toshimitsu H; Yoshimoto Y; Augustine CK; Padussis JC; Yoo JS; Angelica Selim M; Pruitt SK; Friedman HS; Ali-Osman F; Tyler DS
Ann Surg Oncol; 2010 Aug; 17(8):2247-54. PubMed ID: 20182810
[TBL] [Abstract][Full Text] [Related]
20. The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
Reuland SN; Goldstein NB; Partyka KA; Cooper DA; Fujita M; Norris DA; Shellman YG
PLoS One; 2011; 6(8):e24294. PubMed ID: 21897876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
